Skip to main content
Michele Redell, MD, Pediatric Hematology & Oncology, Houston, TX

Michele Simmons Redell MD


Assistant Professor, Pediatrics, Baylor College of Medicine

Join to View Full Profile
  • 6701 Fannin St.Suite 1400Houston, TX 77030

  • Phone+1 832-824-4635

Dr. Redell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Baylor College of Medicine
    Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2001 - 2004
  • Baylor College of Medicine (Houston)
    Baylor College of Medicine (Houston)Residency, Pediatrics, 1998 - 2001
  • University of Washington School of Medicine
    University of Washington School of MedicineClass of 1998
  • University of Washington
    University of WashingtonPh.D., Pharmacology, 1996
  • Brown University
    Brown UniversitySc.B., Neural Science, 1988

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2002 - 2025
  • Pediatrics
    American Board of Pediatrics Pediatrics
  • Pediatric Hematology-Oncology
    American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

  • Chief Fellow Pediatric Hematology-Oncology, Baylor College of Medicine, 2003

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Drug Targeting of NR4A Nuclear Receptors for Treatment of Acute Myeloid Leukemia  
    Michele Redell, MD, Nature
  • Ligand-induced Stat3 signaling increases at relapse and is associated with outcome in pediatric AML: A Report from the Children’s Oncology Group  
    Stevens, A.M., Ruiz, M.J, Gerbing, R.B., Alonzo, T.A., Gamis, A. and Redell, M.S., Haematologica, 1/1/2015
  • Rhodium(II) proximity-labeling identifies a novel target site on STAT3 for inhibitors with potent anti-leukemia activity  
    Minus, M., Liu, W., Vohidov, F., Kasembeli, M., Long, X., Krueger, M., Stevens, A., Kolosov, M., Sison, E., Tweardy, D., Redell, M. and Ball, Z., Angew. Chemie., 1/1/2015
  • Join now to see all

Abstracts/Posters

  • Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Myeloid Leukemia in the Contemporary Era
    Michele Redell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Enhancing the Effect of CLL-1 CAR T Cells with Interleukin-15 for Treatment of Acute Myeloid Leukemia
    Michele Redell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Inhibition of BMP-Smad Pathway Reduces Leukemic Stemness in Pediatric AML
    Michele Redell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Signaling Responses to Stroma-Derived Soluble Factors Are Associated with Outcome and with Expression of Microenvironment-Related Genes in Pediatric AML 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Grant Support

  • STAT3 Isoforms In Maturation And Survival Of Normal And Malignant Myeloid CellsNational Heart, Lung, And Blood Institute2008–2011

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: